OncoMatch/Clinical Trials/NCT06492837
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Is NCT06492837 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Mosunetuzumab in combination with Zanubrutinib for follicular lymphoma.
Treatment: Mosunetuzumab in combination with Zanubrutinib — This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (positive by flow cytometry or immunohistochemistry)
cFL (CD20+ by flow cytometry or immunohistochemistry)
Disease stage
Excluded: Stage I, II
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody — systemic therapy
At least one and up to three lines of systemic therapy containing an anti-CD20 antibody (anti-CD20 alone and/or in combination with radiotherapy is not considered as a line of therapy).
Cannot have received: Bruton's tyrosine kinase inhibitor
Prior exposure to a Bruton's tyrosine kinase (BTK) inhibitor (BTKi).
Cannot have received: anti-CD20xCD3 bispecific antibody
Prior exposure to an anti-CD20xCD3 bispecific antibody (bsAbs).
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior allogeneic hematopoietic stem cell transplantation.
Cannot have received: CAR-T cell therapy
Exception: within 90 days prior to first therapy administration
Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 90 days prior to first therapy administration.
Lab requirements
Blood counts
ANC > 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L; Hemoglobin ≥ 9 g/dL
Kidney function
creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula, normalized to 1.72 m2)
Liver function
AST and ALT ≤ 2.5 x ULN; Bilirubin ≤1.5 x ULN (unless due to Gilbert's syndrome or non-hepatic origin)
Adequate hematological counts defined as follows: Absolute neutrophil count (ANC) > 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L; Hemoglobin ≥ 9 g/dL. Adequate renal function defined as creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula, normalized to 1.72 m2). Adequate hepatic function per local laboratory reference range as follows: AST and ALT ≤ 2.5 x ULN; Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06492837 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Bruton's tyrosine kinase inhibitor, anti-CD20xCD3 bispecific antibody, allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages